Lecanemab, sold under the name Leqembi, is a monoclonal antibody therapy for Alzheimer's disease that clears toxic amyloid ...
Scientists have failed to show that weight-loss wonder drug semaglutide slows the progress of Alzheimer's disease (AD), as ...
A new study suggests you may want to pay better attention to your HDL cholesterol — but not for the reason you might think.
32mon MSN
Immediate treatment for traumatic brain injuries linked to lower risk for Alzheimer's disease
Getting treatment within one week of a serious head injury can reduce the risk of developing Alzheimer's disease by up to 41% ...
MedPage Today on MSN
Highly Anticipated Alzheimer's Trials Yield Disappointing Results for GLP-1 Drug
The biomarker improvements in the EVOKE studies are worth noting, observed Howard Fillit, MD, of the Alzheimer's Drug ...
New research published in the journal Nature suggests that modest doses of lithium orotate may prevent or even reverse ...
Three years after Chris Hemsworth shared he had a gene that elevates his likelihood of developing Alzheimer’s, he detailed ...
In people at risk for Alzheimer’s disease, researchers linked minimal to moderate physical activity to a 3-to 7-year delay in cognitive symptoms.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results